IBDEI0PU.m

IBDEI0PU ; ; 01-FEB-2022

 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022

 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y

Q Q

 ;;^UTILITY(U,$J,358.3,11616,1,4,0)

 ;;=4^I13.11

 ;;^UTILITY(U,$J,358.3,11616,2)

 ;;=^5007069

 ;;^UTILITY(U,$J,358.3,11617,0)

 ;;=I13.2^^46^563^7

 ;;^UTILITY(U,$J,358.3,11617,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,11617,1,3,0)

 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD

 ;;^UTILITY(U,$J,358.3,11617,1,4,0)

 ;;=4^I13.2

 ;;^UTILITY(U,$J,358.3,11617,2)

 ;;=^5007070

 ;;^UTILITY(U,$J,358.3,11618,0)

 ;;=I70.1^^46^563^3

 ;;^UTILITY(U,$J,358.3,11618,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,11618,1,3,0)

 ;;=3^Atherosclerosis of Renal Artery

 ;;^UTILITY(U,$J,358.3,11618,1,4,0)

 ;;=4^I70.1

 ;;^UTILITY(U,$J,358.3,11618,2)

 ;;=^269760

 ;;^UTILITY(U,$J,358.3,11619,0)

 ;;=I77.3^^46^563^2

 ;;^UTILITY(U,$J,358.3,11619,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,11619,1,3,0)

 ;;=3^Arterial Fibromuscular Dysplasia

 ;;^UTILITY(U,$J,358.3,11619,1,4,0)

 ;;=4^I77.3

 ;;^UTILITY(U,$J,358.3,11619,2)

 ;;=^5007812

 ;;^UTILITY(U,$J,358.3,11620,0)

 ;;=E26.02^^46^563^5

 ;;^UTILITY(U,$J,358.3,11620,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,11620,1,3,0)

 ;;=3^Glucocorticoid-Remediable Aldosteronism

 ;;^UTILITY(U,$J,358.3,11620,1,4,0)

 ;;=4^E26.02

 ;;^UTILITY(U,$J,358.3,11620,2)

 ;;=^329904

 ;;^UTILITY(U,$J,358.3,11621,0)

 ;;=I12.9^^46^563^14

 ;;^UTILITY(U,$J,358.3,11621,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,11621,1,3,0)

 ;;=3^Hypertensive CKD Stage 1-4

 ;;^UTILITY(U,$J,358.3,11621,1,4,0)

 ;;=4^I12.9

 ;;^UTILITY(U,$J,358.3,11621,2)

 ;;=^5007066

 ;;^UTILITY(U,$J,358.3,11622,0)

 ;;=I12.0^^46^563^15

 ;;^UTILITY(U,$J,358.3,11622,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,11622,1,3,0)

 ;;=3^Hypertensive CKD Stage 5 or ESRD

 ;;^UTILITY(U,$J,358.3,11622,1,4,0)

 ;;=4^I12.0

 ;;^UTILITY(U,$J,358.3,11622,2)

 ;;=^5007065

 ;;^UTILITY(U,$J,358.3,11623,0)

 ;;=I13.0^^46^563^6

 ;;^UTILITY(U,$J,358.3,11623,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,11623,1,3,0)

 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney

 ;;^UTILITY(U,$J,358.3,11623,1,4,0)

 ;;=4^I13.0

 ;;^UTILITY(U,$J,358.3,11623,2)

 ;;=^5007067

 ;;^UTILITY(U,$J,358.3,11624,0)

 ;;=I13.10^^46^563^9

 ;;^UTILITY(U,$J,358.3,11624,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,11624,1,3,0)

 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney

 ;;^UTILITY(U,$J,358.3,11624,1,4,0)

 ;;=4^I13.10

 ;;^UTILITY(U,$J,358.3,11624,2)

 ;;=^5007068

 ;;^UTILITY(U,$J,358.3,11625,0)

 ;;=I15.1^^46^563^11

 ;;^UTILITY(U,$J,358.3,11625,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,11625,1,3,0)

 ;;=3^Hypertension Secondary to Oth Renal Disorders

 ;;^UTILITY(U,$J,358.3,11625,1,4,0)

 ;;=4^I15.1

 ;;^UTILITY(U,$J,358.3,11625,2)

 ;;=^5007072

 ;;^UTILITY(U,$J,358.3,11626,0)

 ;;=I15.2^^46^563^10

 ;;^UTILITY(U,$J,358.3,11626,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,11626,1,3,0)

 ;;=3^Hypertension Secondary to Endocrine Disorders

 ;;^UTILITY(U,$J,358.3,11626,1,4,0)

 ;;=4^I15.2

 ;;^UTILITY(U,$J,358.3,11626,2)

 ;;=^5007073

 ;;^UTILITY(U,$J,358.3,11627,0)

 ;;=I50.1^^46^563^16

 ;;^UTILITY(U,$J,358.3,11627,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,11627,1,3,0)

 ;;=3^Left Ventricular Failure

 ;;^UTILITY(U,$J,358.3,11627,1,4,0)

 ;;=4^I50.1

 ;;^UTILITY(U,$J,358.3,11627,2)

 ;;=^5007238

 ;;^UTILITY(U,$J,358.3,11628,0)

 ;;=E26.09^^46^563^17

 ;;^UTILITY(U,$J,358.3,11628,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,11628,1,3,0)

 ;;=3^Primary Hyperaldosteronism,Other

 ;;^UTILITY(U,$J,358.3,11628,1,4,0)

 ;;=4^E26.09

--- Routine Detail   --- with STRUCTURED ROUTINE LISTING ---IBDEI0PU   3783     printed  Feb 18, 2025@23:19:48                                                                                                                                                                                                    Page 2

IBDEI0PU  ; ; 01-FEB-2022

 +1       ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022

 +2        if 'DIFQR(358.3)

               QUIT 

           FOR I=1:2

               SET X=$TEXT(Q+I)

               if X=""

                   QUIT 

               SET Y=$EXTRACT($TEXT(Q+I+1),4,999)

               SET X=$EXTRACT(X,4,999)

               if $ASCII(Y)=126

                   SET I=I+1

                   SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)

               if $ASCII(Y)=61

                   SET Y=$EXTRACT(Y,2,999)

               XECUTE NO

              IF '$TEST

                   SET @X=Y

Q          QUIT 

 +1       ;;^UTILITY(U,$J,358.3,11616,1,4,0)

 +2       ;;=4^I13.11

 +3       ;;^UTILITY(U,$J,358.3,11616,2)

 +4       ;;=^5007069

 +5       ;;^UTILITY(U,$J,358.3,11617,0)

 +6       ;;=I13.2^^46^563^7

 +7       ;;^UTILITY(U,$J,358.3,11617,1,0)

 +8       ;;=^358.31IA^4^2

 +9       ;;^UTILITY(U,$J,358.3,11617,1,3,0)

 +10      ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD

 +11      ;;^UTILITY(U,$J,358.3,11617,1,4,0)

 +12      ;;=4^I13.2

 +13      ;;^UTILITY(U,$J,358.3,11617,2)

 +14      ;;=^5007070

 +15      ;;^UTILITY(U,$J,358.3,11618,0)

 +16      ;;=I70.1^^46^563^3

 +17      ;;^UTILITY(U,$J,358.3,11618,1,0)

 +18      ;;=^358.31IA^4^2

 +19      ;;^UTILITY(U,$J,358.3,11618,1,3,0)

 +20      ;;=3^Atherosclerosis of Renal Artery

 +21      ;;^UTILITY(U,$J,358.3,11618,1,4,0)

 +22      ;;=4^I70.1

 +23      ;;^UTILITY(U,$J,358.3,11618,2)

 +24      ;;=^269760

 +25      ;;^UTILITY(U,$J,358.3,11619,0)

 +26      ;;=I77.3^^46^563^2

 +27      ;;^UTILITY(U,$J,358.3,11619,1,0)

 +28      ;;=^358.31IA^4^2

 +29      ;;^UTILITY(U,$J,358.3,11619,1,3,0)

 +30      ;;=3^Arterial Fibromuscular Dysplasia

 +31      ;;^UTILITY(U,$J,358.3,11619,1,4,0)

 +32      ;;=4^I77.3

 +33      ;;^UTILITY(U,$J,358.3,11619,2)

 +34      ;;=^5007812

 +35      ;;^UTILITY(U,$J,358.3,11620,0)

 +36      ;;=E26.02^^46^563^5

 +37      ;;^UTILITY(U,$J,358.3,11620,1,0)

 +38      ;;=^358.31IA^4^2

 +39      ;;^UTILITY(U,$J,358.3,11620,1,3,0)

 +40      ;;=3^Glucocorticoid-Remediable Aldosteronism

 +41      ;;^UTILITY(U,$J,358.3,11620,1,4,0)

 +42      ;;=4^E26.02

 +43      ;;^UTILITY(U,$J,358.3,11620,2)

 +44      ;;=^329904

 +45      ;;^UTILITY(U,$J,358.3,11621,0)

 +46      ;;=I12.9^^46^563^14

 +47      ;;^UTILITY(U,$J,358.3,11621,1,0)

 +48      ;;=^358.31IA^4^2

 +49      ;;^UTILITY(U,$J,358.3,11621,1,3,0)

 +50      ;;=3^Hypertensive CKD Stage 1-4

 +51      ;;^UTILITY(U,$J,358.3,11621,1,4,0)

 +52      ;;=4^I12.9

 +53      ;;^UTILITY(U,$J,358.3,11621,2)

 +54      ;;=^5007066

 +55      ;;^UTILITY(U,$J,358.3,11622,0)

 +56      ;;=I12.0^^46^563^15

 +57      ;;^UTILITY(U,$J,358.3,11622,1,0)

 +58      ;;=^358.31IA^4^2

 +59      ;;^UTILITY(U,$J,358.3,11622,1,3,0)

 +60      ;;=3^Hypertensive CKD Stage 5 or ESRD

 +61      ;;^UTILITY(U,$J,358.3,11622,1,4,0)

 +62      ;;=4^I12.0

 +63      ;;^UTILITY(U,$J,358.3,11622,2)

 +64      ;;=^5007065

 +65      ;;^UTILITY(U,$J,358.3,11623,0)

 +66      ;;=I13.0^^46^563^6

 +67      ;;^UTILITY(U,$J,358.3,11623,1,0)

 +68      ;;=^358.31IA^4^2

 +69      ;;^UTILITY(U,$J,358.3,11623,1,3,0)

 +70      ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney

 +71      ;;^UTILITY(U,$J,358.3,11623,1,4,0)

 +72      ;;=4^I13.0

 +73      ;;^UTILITY(U,$J,358.3,11623,2)

 +74      ;;=^5007067

 +75      ;;^UTILITY(U,$J,358.3,11624,0)

 +76      ;;=I13.10^^46^563^9

 +77      ;;^UTILITY(U,$J,358.3,11624,1,0)

 +78      ;;=^358.31IA^4^2

 +79      ;;^UTILITY(U,$J,358.3,11624,1,3,0)

 +80      ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney

 +81      ;;^UTILITY(U,$J,358.3,11624,1,4,0)

 +82      ;;=4^I13.10

 +83      ;;^UTILITY(U,$J,358.3,11624,2)

 +84      ;;=^5007068

 +85      ;;^UTILITY(U,$J,358.3,11625,0)

 +86      ;;=I15.1^^46^563^11

 +87      ;;^UTILITY(U,$J,358.3,11625,1,0)

 +88      ;;=^358.31IA^4^2

 +89      ;;^UTILITY(U,$J,358.3,11625,1,3,0)

 +90      ;;=3^Hypertension Secondary to Oth Renal Disorders

 +91      ;;^UTILITY(U,$J,358.3,11625,1,4,0)

 +92      ;;=4^I15.1

 +93      ;;^UTILITY(U,$J,358.3,11625,2)

 +94      ;;=^5007072

 +95      ;;^UTILITY(U,$J,358.3,11626,0)

 +96      ;;=I15.2^^46^563^10

 +97      ;;^UTILITY(U,$J,358.3,11626,1,0)

 +98      ;;=^358.31IA^4^2

 +99      ;;^UTILITY(U,$J,358.3,11626,1,3,0)

 +100     ;;=3^Hypertension Secondary to Endocrine Disorders

 +101     ;;^UTILITY(U,$J,358.3,11626,1,4,0)

 +102     ;;=4^I15.2

 +103     ;;^UTILITY(U,$J,358.3,11626,2)

 +104     ;;=^5007073

 +105     ;;^UTILITY(U,$J,358.3,11627,0)

 +106     ;;=I50.1^^46^563^16

 +107     ;;^UTILITY(U,$J,358.3,11627,1,0)

 +108     ;;=^358.31IA^4^2

 +109     ;;^UTILITY(U,$J,358.3,11627,1,3,0)

 +110     ;;=3^Left Ventricular Failure

 +111     ;;^UTILITY(U,$J,358.3,11627,1,4,0)

 +112     ;;=4^I50.1

 +113     ;;^UTILITY(U,$J,358.3,11627,2)

 +114     ;;=^5007238

 +115     ;;^UTILITY(U,$J,358.3,11628,0)

 +116     ;;=E26.09^^46^563^17

 +117     ;;^UTILITY(U,$J,358.3,11628,1,0)

 +118     ;;=^358.31IA^4^2

 +119     ;;^UTILITY(U,$J,358.3,11628,1,3,0)

 +120     ;;=3^Primary Hyperaldosteronism,Other

 +121     ;;^UTILITY(U,$J,358.3,11628,1,4,0)

 +122     ;;=4^E26.09